Back to List View Graph View

DNA topoisomerase I

Topoisomerase 1 Dmel_CG6146 is the Drosophila melanogaster ortholog of human DNA topoisomerase I (TOP1), encoded by CG6146. topoisomerase I resolves the topological strain that accumulates ahead of replication forks and transcribing polymerases: it cleaves one strand of the duplex, forming a transient covalent intermediate — the TOP1 cleavage complex (TOP1cc), in which an active-site tyrosine is linked to the 3′ end of the nick — allows the DNA to rotate about the intact strand, and then reseals it.

Where the papers sit

11 papers from the last 6 months study DNA topoisomerase I directly · updated from PubMed 27 Oct 2026

Study type 0 clinical trials · 1 observational · 8 preclinical · 2 unclassified

Themes one subject · 1 new direction

Those 11 are all about one subject.

  • Topoisomerase I Cancer Therapy

    TOP1-directed cancer treatment is moving toward combination strategies, targeted delivery, and engineered payloads rather than conventional camptothecin alone. CDK7 inhibition, PARP1 co-targeting, camptothecin–niraparib conjugates, and TOP1 degraders are recurring approaches. ADC studies emphasize tumor selectivity and safety, while cGAS-STING activation and immunogenic cell death broaden therapeutic goals. Delivery and linker stability remain practical barriers, and the cluster also contains an unrelated mandibular tumor-management study.

    11 papers

NEW DIRECTION

Thrombin–PAR1 signaling positions DNA topoisomerase I as an inflammatory signaling effector rather than only a DNA-damage target

The thrombin–PAR1 signaling model in triple-negative breast cancer found that thrombin increased Top1 activity without changing its expression, thereby amplifying NF-κB-dependent cytokine production through Par-4 suppression 42219057May. This departs from the set’s predominant use of DNA topoisomerase I as a pharmacological target or cytotoxic payload that produces DNA damage: Top1 instead functions downstream of coagulation signaling to connect the tumor microenvironment with inflammatory transcription. As a result, Top1 activity becomes a potential mechanistic link—and intervention point—for thrombin-driven inflammation and breast-cancer progression, not merely a means of killing tumor cells.

Papers

The 11 papers from the last 6 months that study DNA topoisomerase I directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Topoisomerase I Cancer Therapy (11)
  1. Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. Science advances · 30 Sept 2026 PMID 42814835
  2. Management of mandibular AOT: outcomes following combined treatment protocol. BMJ case reports · 24 Sept 2026 PMID 42785786
  3. Safety management of anti TROP2 ADCs in patients with breast cancer. Current opinion in oncology · 18 Sept 2026 PMID 42757501
  4. Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of medicinal chemistry · 27 Jul 2026 PMID 42504569
  5. Surface-Confinement Effect Enables Bioorthogonal Drug Release in Tumors. Journal of the American Chemical Society · 17 Jul 2026 PMID 42468144
  6. A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
  7. Soluplus®-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy. International journal of pharmaceutics · 12 Jul 2026 PMID 42437626
  8. Design, synthesis, and biological evaluation of novel selenium-matrine hybrid compounds as topo I -targeted anticancer agents. Bioorganic chemistry · 4 Jul 2026 PMID 42401165
  9. Reprogramming Aromatic Camptothecins into TOP1 Degraders via Synergistic Hydrophobic Tagging and Supramolecular Assembly. Journal of the American Chemical Society · 30 Jun 2026 PMID 42378337
  10. A Case Study on the Impact of Thermal Hydrolysis and Lactone Ring Opening of Linker-Payload on Drug-to-Antibody Ratio Determination in a Topoisomerase I Inhibitor-Based ADC. Bioconjugate chemistry · 4 Jun 2026 PMID 42237689
  11. Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression. Cancer letters · 31 May 2026 PMID 42219057

By study type

Observational studies and case reports (1)
  1. Management of mandibular AOT: outcomes following combined treatment protocol. BMJ case reports · 24 Sept 2026 PMID 42785786
Preclinical: animal, cell and lab studies (8)
  1. Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. Science advances · 30 Sept 2026 PMID 42814835
  2. Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of medicinal chemistry · 27 Jul 2026 PMID 42504569
  3. Surface-Confinement Effect Enables Bioorthogonal Drug Release in Tumors. Journal of the American Chemical Society · 17 Jul 2026 PMID 42468144
  4. A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
  5. Soluplus®-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy. International journal of pharmaceutics · 12 Jul 2026 PMID 42437626
  6. Design, synthesis, and biological evaluation of novel selenium-matrine hybrid compounds as topo I -targeted anticancer agents. Bioorganic chemistry · 4 Jul 2026 PMID 42401165
  7. A Case Study on the Impact of Thermal Hydrolysis and Lactone Ring Opening of Linker-Payload on Drug-to-Antibody Ratio Determination in a Topoisomerase I Inhibitor-Based ADC. Bioconjugate chemistry · 4 Jun 2026 PMID 42237689
  8. Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression. Cancer letters · 31 May 2026 PMID 42219057
Unclassified: not yet indexed with MeSH (2)
  1. Safety management of anti TROP2 ADCs in patients with breast cancer. Current opinion in oncology · 18 Sept 2026 PMID 42757501
  2. Reprogramming Aromatic Camptothecins into TOP1 Degraders via Synergistic Hydrophobic Tagging and Supramolecular Assembly. Journal of the American Chemical Society · 30 Jun 2026 PMID 42378337